FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1932592676> ?p ?o ?g. }

• W1932592676 abstract "Background Diabetic kidney disease (DKD) is associated with increased morbidity and mortality, mostly relating to cardiovascular complications. The relevance of inflammation in the pathogenesis of DKD has been investigated in recent years, and it has been shown that inflammatory markers are higher in people with DKD compared with the wider population. Pentoxifylline is a methylxanthine phosphodiesterase inhibitor with favourable anti‐inflammatory effects and immunoregulatory properties. The anti‐inflammatory effects conferred by pentoxifylline may be beneficial in the management of DKD. Objectives To assess the benefits and harms of pentoxifylline for treating people with DKD. Search methods We searched the Cochrane Renal Group's specialised register (January 2012), CENTRAL (Issue 12, 2011), MEDLINE, EMBASE and four Chinese biomedical literature databases (CBM‐disc, 1979 to July 2009), Chinese Science and Technique Journals Database (VIP, until July 2009), China National Knowledge Infrastructure (CNKI, until July 2009) and WanFang database (until July 2009). Selection criteria All randomised controlled trials (RCTs) and quasi‐RCTs studying the benefits and harms of pentoxifylline for DKD. Data collection and analysis Data were extracted independently by two authors. Meta‐analyses were performed when more than one study provided data on a comparable outcome in sufficiently similar patients. Results of dichotomous outcomes were expressed as risk ratios (RR) with 95% confidence intervals (CI). Mean differences (MD) were calculated to assess the effects of treatment where outcomes were expressed on continuous scales, and standardised mean differences (SMD) calculated where different scales were used. Data was pooled using the random effects model. Adverse effects were assessed using descriptive techniques and where possible, risk differences (RD) with 95% CI. Main results We identified 17 studies that included a total of 991 participants with DKD which met our inclusion criteria. Overall, the methodological quality of included studies was low: 4/17 reported the method of randomisation, 13/17 did not; no study described the method of random allocation; 4/17 studies were considered to be at high risk of bias and 13/17 were considered to have unclear risk for incomplete outcome data reporting; 9/17 studies were at low risk bias and in 8/17 the risk of bias was unclear for selective outcome reporting. Compared with placebo, pentoxifylline significantly reduced serum creatinine (SCr) (MD ‐0.10 mg/dL, 95% CI ‐0.17 to ‐0.03), albuminuria (SMD ‐2.28, 95% CI ‐3.85 to ‐0.70) and overt proteinuria (MD ‐428.58 µg/min, 95% CI ‐661.65 to ‐195.50), but there was no difference in creatinine clearance (CrCl) (MD ‐5.18 mL/min, 95% CI ‐15.55 to 5.19). When compared with routine treatment alone, pentoxifylline did not significantly reduce SCr (MD 0.00 mg/dL, 95% CI ‐0.06 to 0.07) or blood pressure (systolic (SBP): MD ‐0.28 mm Hg, 95% CI ‐2.20 to 1.63; diastolic (DBP): MD ‐0.15 mm Hg, 95% CI ‐1.44 to 1.14), but did significantly reduce albuminuria (SMD 0.62, 95% CI 0.18 to 1.07) and proteinuria (MD 0.46 g/24 h, 95% CI 0.17 to 0.74). There was no significant difference in SCr (MD 0.00 mg/dL, 95% CI ‐0.08 to 0.07), albuminuria (MD ‐8.79 µg/min, 95% CI ‐27.18 to 9.59), proteinuria (MD ‐0.01 g/24 h, 95% CI ‐0.03 to 0.01) or blood pressure (SBP: MD 1.46 mm Hg, 95% CI ‐0.57 to 3.50; DBP: MD 1.37 mm Hg, 95% CI ‐0.23 to 2.98) between pentoxifylline and the active comparator (captopril or clonidine/methyldopa) for patients with type 1 and type 2 DKD. CrCl was significantly increased when pentoxifylline was compared to clonidine/methyldopa (MD 10.90 mL/min, 95% CI ‐1.40 to 20.40) but not with captopril (MD 3.26 mL/min, 95% CI ‐1.05 to 7.59). No data were available on the incidence of end‐stage kidney disease (ESKD), time to ESKD, quality of life, or all‐cause mortality. The adverse events of pentoxifylline were mild; no serious adverse events were reported in any of the included studies. Authors' conclusions From the available evidence, pentoxifylline seems to offer some beneficial effects in renal function improvement and reduction in albuminuria and proteinuria, with no obvious serious adverse effects for patients with DKD. However, most studies were poorly reported, small, and methodologically flawed. Evidence to support the use of pentoxifylline for DKD was insufficient to develop recommendations for its use in this patient population. Rigorously designed, randomised, multicentre, large scale studies of pentoxifylline for DKD are needed to further assess its therapeutic effects." @default.
• W1932592676 created "2016-06-24" @default.
• W1932592676 creator A5007054561 @default.
• W1932592676 creator A5018583394 @default.
• W1932592676 creator A5027835055 @default.
• W1932592676 creator A5036729929 @default.
• W1932592676 creator A5057729099 @default.
• W1932592676 creator A5089024368 @default.
• W1932592676 date "2012-02-15" @default.
• W1932592676 modified "2023-09-25" @default.
• W1932592676 title "Pentoxifylline for diabetic kidney disease" @default.
• W1932592676 cites W146573797 @default.
• W1932592676 cites W1775321216 @default.
• W1932592676 cites W1976415149 @default.
• W1932592676 cites W1979285610 @default.
• W1932592676 cites W1981494429 @default.
• W1932592676 cites W1982341832 @default.
• W1932592676 cites W1982677235 @default.
• W1932592676 cites W1988928503 @default.
• W1932592676 cites W1989657193 @default.
• W1932592676 cites W1990652416 @default.
• W1932592676 cites W1992234212 @default.
• W1932592676 cites W1996610877 @default.
• W1932592676 cites W1999917583 @default.
• W1932592676 cites W2001434990 @default.
• W1932592676 cites W2003332051 @default.
• W1932592676 cites W2004256445 @default.
• W1932592676 cites W2004617913 @default.
• W1932592676 cites W2005651168 @default.
• W1932592676 cites W2008904879 @default.
• W1932592676 cites W2015124974 @default.
• W1932592676 cites W2015685909 @default.
• W1932592676 cites W2016386877 @default.
• W1932592676 cites W2019406582 @default.
• W1932592676 cites W2025746540 @default.
• W1932592676 cites W2026754948 @default.
• W1932592676 cites W2027718752 @default.
• W1932592676 cites W2028853636 @default.
• W1932592676 cites W2033645058 @default.
• W1932592676 cites W2044724084 @default.
• W1932592676 cites W2049227123 @default.
• W1932592676 cites W2063270035 @default.
• W1932592676 cites W2064911760 @default.
• W1932592676 cites W2065447230 @default.
• W1932592676 cites W2069091142 @default.
• W1932592676 cites W2070791298 @default.
• W1932592676 cites W2079146383 @default.
• W1932592676 cites W2106177899 @default.
• W1932592676 cites W2108192985 @default.
• W1932592676 cites W2108554136 @default.
• W1932592676 cites W2108595845 @default.
• W1932592676 cites W2113389249 @default.
• W1932592676 cites W2113752582 @default.
• W1932592676 cites W2116111001 @default.
• W1932592676 cites W2125435699 @default.
• W1932592676 cites W2133256067 @default.
• W1932592676 cites W2134338262 @default.
• W1932592676 cites W2153549777 @default.
• W1932592676 cites W2160795579 @default.
• W1932592676 cites W2167761850 @default.
• W1932592676 cites W2168014540 @default.
• W1932592676 cites W2317521667 @default.
• W1932592676 cites W2326273516 @default.
• W1932592676 cites W2331364533 @default.
• W1932592676 cites W4214559180 @default.
• W1932592676 cites W4233562854 @default.
• W1932592676 cites W4235342727 @default.
• W1932592676 cites W4246187706 @default.
• W1932592676 cites W4251386432 @default.
• W1932592676 doi "https://doi.org/10.1002/14651858.cd006800.pub2" @default.
• W1932592676 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22336824" @default.
• W1932592676 hasPublicationYear "2012" @default.
• W1932592676 type Work @default.
• W1932592676 sameAs 1932592676 @default.
• W1932592676 citedByCount "33" @default.
• W1932592676 countsByYear W19325926762013 @default.
• W1932592676 countsByYear W19325926762014 @default.
• W1932592676 countsByYear W19325926762015 @default.
• W1932592676 countsByYear W19325926762016 @default.
• W1932592676 countsByYear W19325926762017 @default.
• W1932592676 countsByYear W19325926762018 @default.
• W1932592676 countsByYear W19325926762020 @default.
• W1932592676 countsByYear W19325926762021 @default.
• W1932592676 countsByYear W19325926762022 @default.
• W1932592676 countsByYear W19325926762023 @default.
• W1932592676 crossrefType "journal-article" @default.
• W1932592676 hasAuthorship W1932592676A5007054561 @default.
• W1932592676 hasAuthorship W1932592676A5018583394 @default.
• W1932592676 hasAuthorship W1932592676A5027835055 @default.
• W1932592676 hasAuthorship W1932592676A5036729929 @default.
• W1932592676 hasAuthorship W1932592676A5057729099 @default.
• W1932592676 hasAuthorship W1932592676A5089024368 @default.
• W1932592676 hasConcept C126322002 @default.
• W1932592676 hasConcept C168563851 @default.
• W1932592676 hasConcept C17744445 @default.
• W1932592676 hasConcept C177713679 @default.
• W1932592676 hasConcept C197934379 @default.
• W1932592676 hasConcept C199539241 @default.
• W1932592676 hasConcept C2776478404 @default.
• W1932592676 hasConcept C2779473830 @default.

• next